drugset / Trial / NCT00538785
A Study to Evaluate MEDI-524 In Children With Hemodynamically Significant Congenital Heart Disease
RandomizedParallel-groupQuadruple-blindPrevention
Summary
The primary goal was to describe the safety of the investigational product when given monthly to prevent serious respiratory infection among children with significant heart disease.
Timeline
- Start
- 2005-10
- Primary completion
- 2008-06
- Completion
- 2008-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Motavizumab | Monoclonal antibody | 15 mg/kg | Intramuscular |
| Comparator | Palivizumab | Monoclonal antibody | 15 mg/kg | Intramuscular |